Dulaglutide
Also known as: Trulicity, LY2189265, GLP-1 Fc Fusion
A long-acting GLP-1 receptor agonist for type 2 diabetes and weight management.
Overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist that combines a GLP-1 analog with an Fc fragment for extended duration. It is administered once weekly for type 2 diabetes and has significant weight loss effects. It also provides cardiovascular benefits.
Mechanism of Action
Activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The Fc fusion extends half-life to allow weekly dosing.
Pharmacokinetics
Half-life ~5 days. Weekly subcutaneous dosing. Renal/hepatic metabolism.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Initiation
0.75 mg
Once weekly
4 weeks
Starting dose
Maintenance
1.5 mg
Once weekly
Ongoing
Can increase to 3mg or 4.5mg
Maximum
4.5 mg
Once weekly
Ongoing
For additional glycemic/weight control
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Average 4-6 kg weight loss in clinical trials
- 2HbA1c reduction of 1-1.5%
- 3Cardiovascular event reduction (REWIND trial)
- 4Once-weekly convenience
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Pancreatitis (rare)
Contraindications
- Personal/family history of MTC
- MEN2 syndrome
- Severe GI disease
- Pancreatitis history
Safety Considerations
FDA approved. GI side effects common initially. Contraindicated in MEN2 or medullary thyroid cancer history. Black box warning for thyroid C-cell tumors in rodents.
Storage Requirements
Refrigerate until use, then room temperature up to 14 days
Scientific References
- 1